Iovance Biotherapeutics, Inc. IOVA Income Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $285.61M+34.3% | $263.5M+60.6% | $250.43M+176% | $241.53M+637% | $212.68M+11,070% | ||
| $180.75M+26.1% | $180.97M+67.7% | $175.65M— | $168.69M— | $143.39M— | ||
| $104.86M+51.3% | $82.54M+47.0% | $74.78M+187% | $72.84M+1,605% | $69.29M+1,184% | ||
| 36.7%+4.1pp | 31.3%-2.9pp | 29.9%+1.2pp | 30.2%+44.9pp | 32.6%+368pp | ||
| $288.23M+4.4% | $301.71M+7.8% | $301.51M+5.6% | $293.37M-4.1% | $276.09M-16.4% | ||
| $147.6M-10.6% | $152.45M-0.1% | $158.38M+13.6% | $163.16M+28.5% | $165.03M+50.9% | ||
| $648.79M+6.1% | $666.86M+19.2% | $666.9M+28.0% | $652.16M+32.5% | $611.46M+30.3% | ||
| -$363.18M+8.9% | -$403.36M-2.0% | -$416.47M+3.1% | -$410.64M+10.6% | -$398.78M+14.7% | ||
| -127.2%+60.3pp | -153.1%+87.8pp | -166.3%+307pp | -170%+1,231pp | -187.5%+24,362pp | ||
| -$354.76M+6.3% | -$393.05M-4.8% | -$398.33M+4.3% | -$389.73M+12.6% | -$378.62M+16.7% | ||
| -$1.08M— | -$2.26M— | —— | —— | —— | ||
| -$353.86M+5.7% | -$390.98M-5.1% | -$397.63M+3.0% | -$389.92M+11.4% | -$375.36M+16.5% | ||
| -123.9%+52.6pp | -148.4%+78.5pp | -158.8%+292pp | -161.4%+1,182pp | -176.5%+23,439pp | ||
| —— | —— | —— | -$1.22+26.9% | -$1.23+31.7% | ||
| -$350.25M+9.5% | -$390.68M-2.0% | -$404.24M+3.3% | -$398.39M+11.0% | -$386.93M+15.1% | ||
| -122.6%+59.3pp | -148.3%+85.2pp | -161.4%+299pp | -164.9%+1,200pp | -181.9%+23,752pp | ||
| -$363.18M+8.9% | -$403.36M-2.0% | -$416.47M+3.1% | -$410.64M+10.6% | -$398.78M+14.7% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Iovance Biotherapeutics, Inc.'s profit margins?
- Gross margin is 36.7% and operating margin is -127.2%, with a -123.9% net margin.
- Where does Iovance Biotherapeutics, Inc.'s income statement data come from?
- Every line is extracted from Iovance Biotherapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.